<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212134</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00024837</org_study_id>
    <secondary_id>U10EY013272</secondary_id>
    <secondary_id>EY013287</secondary_id>
    <secondary_id>EY013272</secondary_id>
    <secondary_id>NEI-108</secondary_id>
    <nct_id>NCT00212134</nct_id>
  </id_info>
  <brief_title>Infant Aphakia Treatment Study (IATS)</brief_title>
  <acronym>IATS</acronym>
  <official_title>Infant Aphakia Treatment Study (IATS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BSN-JOBST Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eye Care and Cure</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to determine whether infants with a unilateral congenital cataract are
      more likely to develop better vision following cataract extraction surgery if they undergo
      primary implantation of an intraocular lens or if they are treated primarily with a contact
      lens. In addition, the study will compare the occurrence of postoperative complications and
      the degree of parental stress between the two treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraocular lenses are now a commonly accepted treatment for cataracts in older children and
      are used increasingly in younger children and infants. Intraocular lenses are superior to
      contact lenses in that they more closely replicate the optics of the crystalline lens, do not
      require daily ongoing care, and ensure at least a partial optical correction at all times.
      The simplicity and improved visual outcome of an intraocular lens correction may make caring
      for a child with a unilateral congenital cataract less stressful for parents. However,
      contact lenses remain the accepted treatment for children under 1 year of age due to concerns
      about the long-term safety of intraocular lenses and the potential for a large myopic shift
      developing in these eyes as they grow. Contact lenses provide excellent visual results in
      infants treated for bilateral congenital cataracts; however, two-thirds of infants treated
      with contact lenses for unilateral congenital cataracts remain legally blind in their aphakic
      eye. These poor visual outcomes are usually ascribed to competition from the sound eye and
      poor compliance with patching and contact lens wear regimens. Data from our pilot study and
      the literature suggest that superior visual results can be obtained if an intraocular lens is
      used to correct unilateral aphakia during infancy, but these eyes will experience more
      complications. Intraocular lenses will be increasingly implanted in infants regardless of
      whether or not we perform this trial. By performing this clinical trial, we can determine if
      the higher rate of complications with intraocular lenses is offset by improved visual outcome
      and decreased parenting stress.

      The Infant Aphakia Treatment Study (IATS) is a multi-center randomized clinical trial
      comparing intraocular lens and contact lens correction for monocular aphakia. Infants will be
      enrolled over a 4 year period. Infants 28 to 210 days of age with a visually significant
      cataract in one eye are eligible. Cataract surgery will be performed in a standardized
      fashion by a surgeon who has been certified for the study. Surgery consists of a lensectomy,
      posterior capsulotomy, and anterior vitrectomy. Infants will be randomized at the time of
      surgery to one of two treatment groups. Infants randomized to the intraocular lens group will
      have an intraocular lens implanted into the capsular bag. Spectacles will subsequently be
      used to correct the residual refractive errors. Infants randomized to the contact lens group
      will be fitted with a contact lens immediately after surgery. Both groups will receive the
      same patching therapy and follow-up. All children will be examined by Investigators at fixed
      intervals using standard protocols with the major endpoint assessed at age 12 months by a
      Traveling Vision Examiner.

      We are currently in a continuation of this project (beyond 5 years) in order to assess which
      of these patients have glaucoma or glaucoma suspect at age 10.5 years. Our goal is to
      understand which type of initial optical correction, an IOL or a CL, results in the best
      long-term visual outcome following unilateral congenital cataract surgery during infancy. Our
      central hypothesis is that primary IOL implantation will result in a better visual outcome.
      The rationale for this proposal is that final visual acuity cannot be determined by 5 years
      of age and the recommendation for early treatment can only be substantiated by adequate
      long-term assessment in this unique cohort. We chose a follow-up to age 10.5 years because it
      will provide a more accurate assessment of visual acuity and will allow us to diagnosis most
      cases of glaucoma.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3 is 10.5-year follow-up study since Phase 1. There is no intervention.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Phase 1 - Age 12 months</time_frame>
    <description>Visual acuity was measured by standard objective testing procedures at 12 months of age. Monocular grating acuity was assessed by the traveling examiner with the Teller Acuity Cards. This test uses cards with black-on-white lines of varying widths and a set distance apart in a square with fixed dimensions, so the thinner the lines, the more there will be on any given card (cycles/cm). The ability to see thinner lines indicates better vision. The cards with lines are presented simultaneously with a gray card and the child's visual attention is noted. It is presumed that the child will preferentially look at the card with the stripes as it is more interesting. When the lines are too thin and close together so as to be indistinguishable from the gray card, no preferential looking will be noted. The card with the thinnest lines that the child will look at is recorded as the best visual acuity in logMAR units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity - Subjective Assessment at Age 4.5 Years.</measure>
    <time_frame>Phase 2 - Age 4.5 Years</time_frame>
    <description>Visual acuity estimates were standardized by using the Electronic Visual Acuity Tester (EVAT) at each clinical site. The IATS patients were tested at 4.5 years of age allowing the use of the HOTV recognition acuity test. The Amblyopia Treatment Study protocol for presentation and determination of best corrected visual acuity was followed. Monocular visual acuity was evaluated using single letter optotypes with surround bars presented on the EVAT. The staircase procedure of the ATS projects was followed as this has documented success and reliability with this age group. In order to familiarize the subjects with the HOTV matching test, this test was introduced at the 4.0 year visit and the 4.25 year visit by experienced site personnel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity - Subjective Assessment at Age 10 Years.</measure>
    <time_frame>Phase 3 Age 10 Years</time_frame>
    <description>Visual acuity assessment using the E-ETDRS protocol will be performed by certified site personnel; patients should be in their best optical correction as determined by the PI either recently or just before the EVA test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With 1 or More Intraoperative Complications at Cataract Surgery</measure>
    <time_frame>Cataract surgery immediately after enrollment</time_frame>
    <description>Percent of Patients with 1 or More Intraoperative Complications at Cataract Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With 1 or More Adverse Events</measure>
    <time_frame>Study enrollment to age 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenting Stress</measure>
    <time_frame>Phase 1 - 3 months post surgery</time_frame>
    <description>The PSI is a 120-item validated self-report measure of parenting stress. PSI is a continuous scale measuring stress with a range of 131 (low stress) to 320 (high stress); the average person's stress scores are between 188 and 252.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Occlusion Therapy</measure>
    <time_frame>Phase 1 - 12 months follow-up</time_frame>
    <description>Parental report of the number of hours children wore an patch to occlude the fellow eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenting Stress</measure>
    <time_frame>Phase 1 - Age 12 Months</time_frame>
    <description>The PSI is a 120-item validated self-report measure of parenting stress. PSI is a continuous scale measuring stress with a range of 131 (low stress) to 320 (high stress); the average person's stress scores are between 188 and 252</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Congenital Cataract</condition>
  <arm_group>
    <arm_group_label>aphakic contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contact lens correction of aphakia
INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aphakic intraocular lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraocular lens implantation
INTERVENTION: At the time of surgery to remove the cataractous natural lens, an intraocular lens was implanted to correct the large hyperopic refractive error induced by the cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contact lens correction of aphakia</intervention_name>
    <description>optical correction of infant surgical aphakia with Contact lens</description>
    <arm_group_label>aphakic contact lens</arm_group_label>
    <other_name>Silsoft aphakic contact lens</other_name>
    <other_name>rigid gas permeable contact lens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraocular lens implantation</intervention_name>
    <description>optical correction of surgical aphakia with intraocular lens</description>
    <arm_group_label>aphakic intraocular lens</arm_group_label>
    <other_name>Alcon SA60AT</other_name>
    <other_name>Alcon MA60AC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Visually significant unilateral congenital cataract (central opacity equal to or
             greater than 3 mm in size).

          -  Cataract surgery performed when the patient is 28 to 210 days of age and at least 41
             post-conceptional weeks.

        Exclusion Criteria:

          -  The cataract is known to be acquired from trauma or as a side-effect of a treatment
             administered postnatally such as radiation or medical therapy.

          -  A corneal diameter less than 9 mm measured in the horizontal meridian using calipers.

          -  An intraocular pressure of 25 mm Hg or greater in the affected eye measured with a
             Perkins tonometer, tonopen, or pneumatonometer.

          -  Persistent fetal vasculature (PFV) causing stretching of the ciliary processes or a
             tractional retinal detachment.

          -  Active uveitis or signs suggestive of a previous episode of uveitis such as posterior
             synechiae or keratic precipitates.

          -  The child is the product of a pre-term pregnancy (&lt;36 gestational weeks). Screening
             for prematurity will be based on the clinician's best assessment of gestational age.
             If a physician is uncertain regarding the gestational age, review of medical records
             or contact with the pediatrician and/or obstetrician should be used to confirm
             gestational age at delivery. Unless a clinician is uncertain as to whether a child was
             born at less than 36 weeks or not, confirmation of gestational age via medical record
             review may be delayed until after enrollment.

          -  Retinal disease that may limit the visual potential of the eye such as retinopathy of
             prematurity.

          -  Previous intraocular surgery.

          -  Optic nerve disease that may limit the visual potential of the eye such as optic nerve
             hypoplasia.

          -  The fellow eye has ocular disease that might reduce its visual potential.

          -  The child has a medical condition known to limit the ability to obtain visual acuity
             at 12 months or 4 years of age.

          -  Refusal by the Parent/Legal Guardian to sign an informed consent or to be randomized
             to one of the two treatment groups.

          -  Follow-up of the child is not feasible because the child would not be able to return
             for regular follow-up examinations and the outcome assessments (e.g. transportation
             difficulties, relocation, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>210 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Lambert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-4197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-2236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Ophthalmology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nei.nih.gov/health/clinicalstudies/</url>
    <description>NEI Clinical Studies Database--Infant Aphakia Treatment Study (IATS)</description>
  </link>
  <link>
    <url>http://web1.sph.emory.edu/IATS</url>
    <description>Infant Aphakia Treatment Study (IATS)</description>
  </link>
  <reference>
    <citation>Bothun ED, Lynn MJ, Lambert SR. Author reply: To PMID 23419803. Ophthalmology. 2014 Oct;121(10):e53. doi: 10.1016/j.ophtha.2014.05.011. Epub 2014 Jun 6.</citation>
    <PMID>24909820</PMID>
  </reference>
  <reference>
    <citation>Traboulsi EI, Vanderveen D, Morrison D, Drews-Botsch CD, Lambert SR; Infant Aphakia Treatment Study Group. Associated systemic and ocular disorders in patients with congenital unilateral cataracts: the Infant Aphakia Treatment Study experience. Eye (Lond). 2016 Sep;30(9):1170-4. doi: 10.1038/eye.2016.124. Epub 2016 Jun 17.</citation>
    <PMID>27315350</PMID>
  </reference>
  <reference>
    <citation>Drews-Botsch C, Celano M, Cotsonis G, Hartmann EE, Lambert SR; Infant Aphakia Treatment Study Group. Association Between Occlusion Therapy and Optotype Visual Acuity in Children Using Data From the Infant Aphakia Treatment Study: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2016 Aug 1;134(8):863-9. doi: 10.1001/jamaophthalmol.2016.1365.</citation>
    <PMID>27228110</PMID>
  </reference>
  <reference>
    <citation>Lambert SR, Plager DA, Lynn MJ, Wilson ME. Visual outcome following the reduction or cessation of patching therapy after early unilateral cataract surgery. Arch Ophthalmol. 2008 Aug;126(8):1071-4. doi: 10.1001/archopht.126.8.1071.</citation>
    <PMID>18695101</PMID>
  </reference>
  <reference>
    <citation>Infant Aphakia Treatment Study Group, Lambert SR, Buckley EG, Drews-Botsch C, DuBois L, Hartmann E, Lynn MJ, Plager DA, Wilson ME. The infant aphakia treatment study: design and clinical measures at enrollment. Arch Ophthalmol. 2010 Jan;128(1):21-7. doi: 10.1001/archophthalmol.2009.350.</citation>
    <PMID>20065212</PMID>
  </reference>
  <reference>
    <citation>Infant Aphakia Treatment Study Group, Lambert SR, Buckley EG, Drews-Botsch C, DuBois L, Hartmann EE, Lynn MJ, Plager DA, Wilson ME. A randomized clinical trial comparing contact lens with intraocular lens correction of monocular aphakia during infancy: grating acuity and adverse events at age 1 year. Arch Ophthalmol. 2010 Jul;128(7):810-8. doi: 10.1001/archophthalmol.2010.101. Epub 2010 May 10.</citation>
    <PMID>20457949</PMID>
  </reference>
  <reference>
    <citation>Plager DA, Lynn MJ, Buckley EG, Wilson ME, Lambert SR; Infant Aphakia Treatment Study Group. Complications, adverse events, and additional intraocular surgery 1 year after cataract surgery in the infant Aphakia Treatment Study. Ophthalmology. 2011 Dec;118(12):2330-4. doi: 10.1016/j.ophtha.2011.06.017. Epub 2011 Sep 16.</citation>
    <PMID>21925737</PMID>
  </reference>
  <reference>
    <citation>Morrison DG, Wilson ME, Trivedi RH, Lambert SR, Lynn MJ; Infant Aphakia Treatment Study Group. Infant Aphakia Treatment Study: effects of persistent fetal vasculature on outcome at 1 year of age. J AAPOS. 2011 Oct;15(5):427-31. doi: 10.1016/j.jaapos.2011.06.004.</citation>
    <PMID>22108353</PMID>
  </reference>
  <reference>
    <citation>Wilson ME, Trivedi RH, Morrison DG, Lambert SR, Buckley EG, Plager DA, Lynn MJ; Infant Aphakia Treatment Study Group. The Infant Aphakia Treatment Study: evaluation of cataract morphology in eyes with monocular cataracts. J AAPOS. 2011 Oct;15(5):421-6. doi: 10.1016/j.jaapos.2011.05.016.</citation>
    <PMID>22108352</PMID>
  </reference>
  <reference>
    <citation>Drews-Botsch CD, Hartmann EE, Celano M; Infant Aphakia Treatment Study Group. Predictors of adherence to occlusion therapy 3 months after cataract extraction in the Infant Aphakia Treatment Study. J AAPOS. 2012 Apr;16(2):150-5. doi: 10.1016/j.jaapos.2011.12.149.</citation>
    <PMID>22525171</PMID>
  </reference>
  <reference>
    <citation>Beck AD, Freedman SF, Lynn MJ, Bothun E, Neely DE, Lambert SR; Infant Aphakia Treatment Study Group. Glaucoma-related adverse events in the Infant Aphakia Treatment Study: 1-year results. Arch Ophthalmol. 2012 Mar;130(3):300-5. doi: 10.1001/archophthalmol.2011.347. Epub 2011 Nov 14.</citation>
    <PMID>22084157</PMID>
  </reference>
  <reference>
    <citation>VanderVeen DK, Nizam A, Lynn MJ, Bothun ED, McClatchey SK, Weakley DR, DuBois LG, Lambert SR; Infant Aphakia Treatment Study Group. Predictability of intraocular lens calculation and early refractive status: the Infant Aphakia Treatment Study. Arch Ophthalmol. 2012 Mar;130(3):293-9. doi: 10.1001/archophthalmol.2011.358.</citation>
    <PMID>22411658</PMID>
  </reference>
  <reference>
    <citation>Russell B, Ward MA, Lynn M, Dubois L, Lambert SR; Infant Aphakia Treatment Study Group. The infant aphakia treatment study contact lens experience: one-year outcomes. Eye Contact Lens. 2012 Jul;38(4):234-9. doi: 10.1097/ICL.0b013e3182562dc0.</citation>
    <PMID>22669008</PMID>
  </reference>
  <reference>
    <citation>Lambert SR, Purohit A, Superak HM, Lynn MJ, Beck AD. Long-term risk of glaucoma after congenital cataract surgery. Am J Ophthalmol. 2013 Aug;156(2):355-361.e2. doi: 10.1016/j.ajo.2013.03.013. Epub 2013 Apr 30.</citation>
    <PMID>23639132</PMID>
  </reference>
  <reference>
    <citation>Carrigan AK, DuBois LG, Becker ER, Lambert SR; Infant Aphakia Treatment Study Group. Cost of intraocular lens versus contact lens treatment after unilateral congenital cataract surgery: retrospective analysis at age 1 year. Ophthalmology. 2013 Jan;120(1):14-9. doi: 10.1016/j.ophtha.2012.07.049. Epub 2012 Oct 6.</citation>
    <PMID>23047003</PMID>
  </reference>
  <reference>
    <citation>Trivedi RH, Lambert SR, Lynn MJ, Wilson ME; Infant Aphakia Treatment Study Group. The role of preoperative biometry in selecting initial contact lens power in the Infant Aphakia Treatment Study. J AAPOS. 2014 Jun;18(3):251-4. doi: 10.1016/j.jaapos.2014.01.012.</citation>
    <PMID>24924278</PMID>
  </reference>
  <reference>
    <citation>Vanderveen DK, Trivedi RH, Nizam A, Lynn MJ, Lambert SR; Infant Aphakia Treatment Study Group. Predictability of intraocular lens power calculation formulae in infantile eyes with unilateral congenital cataract: results from the Infant Aphakia Treatment Study. Am J Ophthalmol. 2013 Dec;156(6):1252-1260.e2. doi: 10.1016/j.ajo.2013.07.014. Epub 2013 Sep 4.</citation>
    <PMID>24011524</PMID>
  </reference>
  <reference>
    <citation>Hartmann EE, Stout AU, Lynn MJ, Yen KG, Kruger SJ, Lambert SR; Infant Aphakia Treatment Study Group; Infant Aphakia Treatment Study Group. Stereopsis results at 4.5 years of age in the infant aphakia treatment study. Am J Ophthalmol. 2015 Jan;159(1):64-70.e1-2. doi: 10.1016/j.ajo.2014.09.028. Epub 2014 Sep 28.</citation>
    <PMID>25261241</PMID>
  </reference>
  <reference>
    <citation>Infant Aphakia Treatment Study Group, Lambert SR, Lynn MJ, Hartmann EE, DuBois L, Drews-Botsch C, Freedman SF, Plager DA, Buckley EG, Wilson ME. Comparison of contact lens and intraocular lens correction of monocular aphakia during infancy: a randomized clinical trial of HOTV optotype acuity at age 4.5 years and clinical findings at age 5 years. JAMA Ophthalmol. 2014 Jun;132(6):676-82.</citation>
    <PMID>24604348</PMID>
  </reference>
  <reference>
    <citation>Kruger SJ, DuBois L, Becker ER, Morrison D, Wilson L, Wilson ME Jr, Lambert SR; Infant Aphakia Treatment Study Group. Cost of intraocular lens versus contact lens treatment after unilateral congenital cataract surgery in the infant aphakia treatment study at age 5 years. Ophthalmology. 2015 Feb;122(2):288-92. doi: 10.1016/j.ophtha.2014.08.037. Epub 2014 Oct 29.</citation>
    <PMID>25439604</PMID>
  </reference>
  <reference>
    <citation>Wall PB, Lee JA, Lynn MJ, Lambert SR, Traboulsi EI; Infant Aphakia Treatment Study Group. The effects of surgical factors on postoperative astigmatism in patients enrolled in the Infant Aphakia Treatment Study (IATS). J AAPOS. 2014 Oct;18(5):441-5. doi: 10.1016/j.jaapos.2014.06.016. Epub 2014 Sep 27.</citation>
    <PMID>25266831</PMID>
  </reference>
  <reference>
    <citation>Bothun ED, Cleveland J, Lynn MJ, Christiansen SP, Vanderveen DK, Neely DE, Kruger SJ, Lambert SR; Infant Aphakic Treatment Study. One-year strabismus outcomes in the Infant Aphakia Treatment Study. Ophthalmology. 2013 Jun;120(6):1227-31. doi: 10.1016/j.ophtha.2012.11.039. Epub 2013 Feb 16.</citation>
    <PMID>23419803</PMID>
  </reference>
  <reference>
    <citation>Freedman SF, Lynn MJ, Beck AD, Bothun ED, Ã–rge FH, Lambert SR; Infant Aphakia Treatment Study Group. Glaucoma-Related Adverse Events in the First 5 Years After Unilateral Cataract Removal in the Infant Aphakia Treatment Study. JAMA Ophthalmol. 2015 Aug;133(8):907-14. doi: 10.1001/jamaophthalmol.2015.1329.</citation>
    <PMID>25996491</PMID>
  </reference>
  <reference>
    <citation>Plager DA, Lynn MJ, Buckley EG, Wilson ME, Lambert SR; Infant Aphakia Treatment Study Group. Complications in the first 5 years following cataract surgery in infants with and without intraocular lens implantation in the Infant Aphakia Treatment Study. Am J Ophthalmol. 2014 Nov;158(5):892-8. doi: 10.1016/j.ajo.2014.07.031. Epub 2014 Jul 29.</citation>
    <PMID>25077835</PMID>
  </reference>
  <reference>
    <citation>Morrison DG, Lynn MJ, Freedman SF, Orge FH, Lambert SR; Infant Aphakia Treatment Study Group. Corneal Changes in Children after Unilateral Cataract Surgery in the Infant Aphakia Treatment Study. Ophthalmology. 2015 Nov;122(11):2186-92. doi: 10.1016/j.ophtha.2015.07.011. Epub 2015 Aug 11.</citation>
    <PMID>26271843</PMID>
  </reference>
  <reference>
    <citation>VanderVeen DK, Trivedi RH, Nizam A, Lynn MJ, Lambert SR. Reply: To PMID 24011524. Am J Ophthalmol. 2014 Jun;157(6):1332-3. doi: 10.1016/j.ajo.2014.02.053.</citation>
    <PMID>24881851</PMID>
  </reference>
  <reference>
    <citation>Kumar P, Lambert SR. Evaluating the evidence for and against the use of IOLs in infants and young children. Expert Rev Med Devices. 2016;13(4):381-9. doi: 10.1586/17434440.2016.1153967. Epub 2016 Feb 29. Review.</citation>
    <PMID>26878234</PMID>
  </reference>
  <reference>
    <citation>Bothun ED, Lynn MJ, Christiansen SP, Neely DE, Vanderveen DK, Kruger SJ, Lambert SR; Infant Aphakia Treatment Study. Sensorimotor outcomes by age 5 years after monocular cataract surgery in the Infant Aphakia Treatment Study (IATS). J AAPOS. 2016 Feb;20(1):49-53. doi: 10.1016/j.jaapos.2015.11.002.</citation>
    <PMID>26917072</PMID>
  </reference>
  <reference>
    <citation>Celano M, Hartmann EE, DuBois LG, Drews-Botsch C; Infant Aphakia Treatment Study Group. Motor skills of children with unilateral visual impairment in the Infant Aphakia Treatment Study. Dev Med Child Neurol. 2016 Feb;58(2):154-9. doi: 10.1111/dmcn.12832. Epub 2015 Jun 17.</citation>
    <PMID>26084944</PMID>
  </reference>
  <reference>
    <citation>Lambert SR, Plager DA, Buckley EG, Wilson ME, DuBois L, Drews-Botsch CD, Hartmann EE, Lynn MJ; Infant Aphakia Treatment Study Group. The Infant Aphakia Treatment Study: further on intra- and postoperative complications in the intraocular lens group. J AAPOS. 2015 Apr;19(2):101-3. doi: 10.1016/j.jaapos.2015.01.012.</citation>
    <PMID>25892038</PMID>
  </reference>
  <reference>
    <citation>Lambert SR, Lynn MJ, Hartmann EE; Infant Aphakia Treatment Study Group. In reply. JAMA Ophthalmol. 2014 Dec;132(12):1492-3. doi: 10.1001/jamaophthalmol.2014.3542.</citation>
    <PMID>25256439</PMID>
  </reference>
  <reference>
    <citation>Celano M, Hartmann EE, Drews-Botsch CD; Infant Aphakia Treatment Study Group. Parenting stress in the infant aphakia treatment study. J Pediatr Psychol. 2013 Jun;38(5):484-93. doi: 10.1093/jpepsy/jst009. Epub 2013 Mar 9.</citation>
    <PMID>23475835</PMID>
  </reference>
  <reference>
    <citation>Lenhart PD, Courtright P, Wilson ME, Lewallen S, Taylor DS, Ventura MC, Bowman R, Woodward L, Ditta LC, Kruger S, Haddad D, El Shakankiri N, Rai SK, Bailey T, Lambert SR. Global challenges in the management of congenital cataract: proceedings of the 4th International Congenital Cataract Symposium held on March 7, 2014, New York, New York. J AAPOS. 2015 Apr;19(2):e1-8. doi: 10.1016/j.jaapos.2015.01.013.</citation>
    <PMID>25892047</PMID>
  </reference>
  <reference>
    <citation>Nguyen M, Shainberg M, Beck AD, Lambert SR. Structural changes of the anterior chamber following cataract surgery during infancy. J Cataract Refract Surg. 2015 Aug;41(8):1784-6. doi: 10.1016/j.jcrs.2015.07.001.</citation>
    <PMID>26432141</PMID>
  </reference>
  <reference>
    <citation>Russell B, DuBois L, Lynn M, Ward MA, Lambert SR; Infant Aphakia Treatment Study Group. The Infant Aphakia Treatment Study Contact Lens Experience to Age 5 Years. Eye Contact Lens. 2017 Nov;43(6):352-357. doi: 10.1097/ICL.0000000000000291.</citation>
    <PMID>27466719</PMID>
  </reference>
  <reference>
    <citation>Lambert SR. The timing of surgery for congenital cataracts: Minimizing the risk of glaucoma following cataract surgery while optimizing the visual outcome. J AAPOS. 2016 Jun;20(3):191-2. doi: 10.1016/j.jaapos.2016.04.003. Epub 2016 May 11.</citation>
    <PMID>27180288</PMID>
  </reference>
  <reference>
    <citation>Celano M, Cotsonis GA, Hartmann EE, Drews-Botsch C; Infant Aphakia Treatment Study Group. Behaviors of children with unilateral vision impairment in the Infant Aphakia Treatment Study. J AAPOS. 2016 Aug;20(4):320-5. doi: 10.1016/j.jaapos.2016.04.008. Epub 2016 Jul 14.</citation>
    <PMID>27424046</PMID>
  </reference>
  <reference>
    <citation>Drews-Botsch C, Cotsonis G, Celano M, Lambert SR. Assessment of Adherence to Visual Correction and Occlusion Therapy in the Infant Aphakia Treatment Study. Contemp Clin Trials Commun. 2016 Aug 15;3:158-166. Epub 2016 May 30.</citation>
    <PMID>27981259</PMID>
  </reference>
  <reference>
    <citation>Lambert SR, DuBois L, Cotsonis G, Hartmann EE, Drews-Botsch C. Factors associated with stereopsis and a good visual acuity outcome among children in the Infant Aphakia Treatment Study. Eye (Lond). 2016 Sep;30(9):1221-8. doi: 10.1038/eye.2016.164. Epub 2016 Jul 29.</citation>
    <PMID>27472216</PMID>
  </reference>
  <reference>
    <citation>Bothun ED, Lynn MJ, Christiansen SP, Kruger SJ, Vanderveen DK, Neely DE, Lambert SR; Infant Aphakic Treatment Study. Strabismus surgery outcomes in the Infant Aphakia Treatment Study (IATS) at age 5 years. J AAPOS. 2016 Dec;20(6):501-505. doi: 10.1016/j.jaapos.2016.09.014. Epub 2016 Nov 2.</citation>
    <PMID>27815186</PMID>
  </reference>
  <reference>
    <citation>Lambert SR, Cotsonis G, DuBois L, Wilson ME, Plager DA, Buckley EG, McClatchey SK; Infant Aphakia Treatment Study Group. Comparison of the rate of refractive growth in aphakic eyes versus pseudophakic eyes in the Infant Aphakia Treatment Study. J Cataract Refract Surg. 2016 Dec;42(12):1768-1773. doi: 10.1016/j.jcrs.2016.09.021.</citation>
    <PMID>28007108</PMID>
  </reference>
  <reference>
    <citation>Cooke DL. Predictability of intraocular lens power calculation formulae in infantile eyes with unilateral congenital cataract: results from the infant aphakia treatment study. Am J Ophthalmol. 2014 Jun;157(6):1332. doi: 10.1016/j.ajo.2014.02.051.</citation>
    <PMID>24881852</PMID>
  </reference>
  <reference>
    <citation>Drews-Botsch CD, Celano M, Kruger S, Hartmann EE; Infant Aphakia Treatment Study. Adherence to occlusion therapy in the first six months of follow-up and visual acuity among participants in the Infant Aphakia Treatment Study (IATS). Invest Ophthalmol Vis Sci. 2012 Jun 5;53(7):3368-75. doi: 10.1167/iovs.11-8457.</citation>
    <PMID>22491410</PMID>
  </reference>
  <reference>
    <citation>Felius J, Busettini C, Lynn MJ, Hartmann EE, Lambert SR; Infant Aphakia Treatment Study Group. Nystagmus and related fixation instabilities following extraction of unilateral infantile cataract in the Infant Aphakia Treatment Study (IATS). Invest Ophthalmol Vis Sci. 2014 Aug 5;55(8):5332-7. doi: 10.1167/iovs.14-14710.</citation>
    <PMID>25097243</PMID>
  </reference>
  <reference>
    <citation>Lambert SR, Lynn MJ, DuBois LG, Cotsonis GA, Hartmann EE, Wilson ME; Infant Aphakia Treatment Study Groups. Axial elongation following cataract surgery during the first year of life in the infant Aphakia Treatment Study. Invest Ophthalmol Vis Sci. 2012 Nov 7;53(12):7539-45. doi: 10.1167/iovs.12-10285.</citation>
    <PMID>23074203</PMID>
  </reference>
  <reference>
    <citation>Wilson ME, Trivedi RH, Weakley DR Jr, Cotsonis GA, Lambert SR; Infant Aphakia Treatment Study Group. Globe Axial Length Growth at Age 5 Years in the Infant Aphakia Treatment Study. Ophthalmology. 2017 May;124(5):730-733. doi: 10.1016/j.ophtha.2017.01.010. Epub 2017 Feb 10.</citation>
    <PMID>28196730</PMID>
  </reference>
  <reference>
    <citation>Weakley DR Jr, Lynn MJ, Dubois L, Cotsonis G, Wilson ME, Buckley EG, Plager DA, Lambert SR; Infant Aphakia Treatment Study Group. Myopic Shift 5 Years after Intraocular Lens Implantation in the Infant Aphakia Treatment Study. Ophthalmology. 2017 Jun;124(6):822-827. doi: 10.1016/j.ophtha.2016.12.040. Epub 2017 Feb 16.</citation>
    <PMID>28215452</PMID>
  </reference>
  <reference>
    <citation>Plager DA, Lynn MJ, Lambert SR, Buckley EG, Wilson ME; Infant Aphakia Treatment Study Group. Reply: To PMID 25077835. Am J Ophthalmol. 2014 Dec;158(6):1361-2. doi: 10.1016/j.ajo.2014.09.019. Epub 2014 Nov 18.</citation>
    <PMID>25457713</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>July 15, 2013</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2015</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Scott Reed Lambert</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cataract surgery</keyword>
  <keyword>intraocular lens</keyword>
  <keyword>contact lens</keyword>
  <keyword>infants</keyword>
  <keyword>aphakia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment 12/23/04 to 01/16/09 at 12 medical clinics.</recruitment_details>
      <pre_assignment_details>Final eligibility determined at pre-operative ocular examination under anesthesia.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aphakic Contact Lens</title>
          <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
        </group>
        <group group_id="P2">
          <title>Aphakic Intraocular Lens</title>
          <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1 (to Age 1 Year)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Complete First Endpoint at 1 Year</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57">Age 1 data collection visit</participants>
                <participants group_id="P2" count="57">Age 1 data collection visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2 (Age 1 Year to Age 5 Years)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57">Visual acuity assessment at Age 4.5 Years and final visit at Age 5 Years.</participants>
                <participants group_id="P2" count="57">Visual acuity assessment at Age 4.5 Years and final visit at Age 5 Years.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56">Patient lost to follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 3 (Age 10 Years)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>On Going</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aphakic Contact Lens</title>
          <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
        </group>
        <group group_id="B2">
          <title>Aphakic Intraocular Lens</title>
          <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>mean/sd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="1.6"/>
                    <measurement group_id="B2" value="2.5" spread="1.6"/>
                    <measurement group_id="B3" value="2.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>28 - 48 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>49 days - 3.0 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.1 - 5.0 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5.1 - 6.8 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Private Insurance</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qualified for Medicaid</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pupil Diameter - Cataractous Eye</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="1.0"/>
                    <measurement group_id="B2" value="3.2" spread="1.0"/>
                    <measurement group_id="B3" value="3.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pupil Diameter - Fellow Eye</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="0.9"/>
                    <measurement group_id="B2" value="3.4" spread="0.9"/>
                    <measurement group_id="B3" value="3.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corneal Diameter - Cataractous Eye</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="0.7"/>
                    <measurement group_id="B2" value="10.5" spread="0.8"/>
                    <measurement group_id="B3" value="10.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corneal Diameter - Fellow Eye</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="0.6"/>
                    <measurement group_id="B2" value="10.8" spread="0.7"/>
                    <measurement group_id="B3" value="10.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular Pressure - Cataractous Eye</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" spread="4.9"/>
                    <measurement group_id="B2" value="11.8" spread="4.9"/>
                    <measurement group_id="B3" value="12.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular Pressure - Fellow Eye</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="5.1"/>
                    <measurement group_id="B2" value="12.9" spread="4.3"/>
                    <measurement group_id="B3" value="12.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Keratometric Power - Cataractous Eye</title>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="2.7"/>
                    <measurement group_id="B2" value="46.4" spread="2.7"/>
                    <measurement group_id="B3" value="46.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Keratometric Power - Fellow Eye</title>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="1.8"/>
                    <measurement group_id="B2" value="45.4" spread="1.9"/>
                    <measurement group_id="B3" value="45.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axial Length - Cataractous Eye</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" spread="1.3"/>
                    <measurement group_id="B2" value="18.1" spread="1.3"/>
                    <measurement group_id="B3" value="18.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axial Length - Fellow Eye</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.4" spread="0.9"/>
                    <measurement group_id="B2" value="18.7" spread="0.9"/>
                    <measurement group_id="B3" value="18.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Refractive Error - Fellow Eye</title>
          <description>Spherical equivalent of the refraction measured under cycloplegia</description>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="1.8"/>
                    <measurement group_id="B2" value="2.3" spread="2.2"/>
                    <measurement group_id="B3" value="2.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>Visual acuity was measured by standard objective testing procedures at 12 months of age. Monocular grating acuity was assessed by the traveling examiner with the Teller Acuity Cards. This test uses cards with black-on-white lines of varying widths and a set distance apart in a square with fixed dimensions, so the thinner the lines, the more there will be on any given card (cycles/cm). The ability to see thinner lines indicates better vision. The cards with lines are presented simultaneously with a gray card and the child's visual attention is noted. It is presumed that the child will preferentially look at the card with the stripes as it is more interesting. When the lines are too thin and close together so as to be indistinguishable from the gray card, no preferential looking will be noted. The card with the thinnest lines that the child will look at is recorded as the best visual acuity in logMAR units.</description>
        <time_frame>Phase 1 - Age 12 months</time_frame>
        <population>The number of participants was determined by the sample size estimate necessary to detect a 0.2 logMAR difference (2 lines on the Snellen chart) in the visual acuity between the two groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Aphakic Contact Lens</title>
            <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly.</description>
          </group>
          <group group_id="O2">
            <title>Aphakic Intraocular Lens</title>
            <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: The refractive error induced by surgical removal of the cataractous natural lens is partially corrected by the implantation of an intraocular lens (IOL) at the time of surgery. This is deemed a permanent correction as the IOL may only be removed in a subsequent surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Visual acuity was measured by standard objective testing procedures at 12 months of age. Monocular grating acuity was assessed by the traveling examiner with the Teller Acuity Cards. This test uses cards with black-on-white lines of varying widths and a set distance apart in a square with fixed dimensions, so the thinner the lines, the more there will be on any given card (cycles/cm). The ability to see thinner lines indicates better vision. The cards with lines are presented simultaneously with a gray card and the child's visual attention is noted. It is presumed that the child will preferentially look at the card with the stripes as it is more interesting. When the lines are too thin and close together so as to be indistinguishable from the gray card, no preferential looking will be noted. The card with the thinnest lines that the child will look at is recorded as the best visual acuity in logMAR units.</description>
          <population>The number of participants was determined by the sample size estimate necessary to detect a 0.2 logMAR difference (2 lines on the Snellen chart) in the visual acuity between the two groups.</population>
          <units>logMAR units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="0.66" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.80" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity - Subjective Assessment at Age 4.5 Years.</title>
        <description>Visual acuity estimates were standardized by using the Electronic Visual Acuity Tester (EVAT) at each clinical site. The IATS patients were tested at 4.5 years of age allowing the use of the HOTV recognition acuity test. The Amblyopia Treatment Study protocol for presentation and determination of best corrected visual acuity was followed. Monocular visual acuity was evaluated using single letter optotypes with surround bars presented on the EVAT. The staircase procedure of the ATS projects was followed as this has documented success and reliability with this age group. In order to familiarize the subjects with the HOTV matching test, this test was introduced at the 4.0 year visit and the 4.25 year visit by experienced site personnel.</description>
        <time_frame>Phase 2 - Age 4.5 Years</time_frame>
        <population>One patient in the intraocular lens group was lost to follow-up.at age 18 months. A second patient in that group had developmental delay and the visual acuity could not be assessed. Therefore, the visual acuity measurements at 4.5 years of age are reported for 55 of the 57 patients randomized to the intraocular lens group.</population>
        <group_list>
          <group group_id="O1">
            <title>Aphakic Contact Lens</title>
            <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
          </group>
          <group group_id="O2">
            <title>Aphakic Intraocular Lens</title>
            <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity - Subjective Assessment at Age 4.5 Years.</title>
          <description>Visual acuity estimates were standardized by using the Electronic Visual Acuity Tester (EVAT) at each clinical site. The IATS patients were tested at 4.5 years of age allowing the use of the HOTV recognition acuity test. The Amblyopia Treatment Study protocol for presentation and determination of best corrected visual acuity was followed. Monocular visual acuity was evaluated using single letter optotypes with surround bars presented on the EVAT. The staircase procedure of the ATS projects was followed as this has documented success and reliability with this age group. In order to familiarize the subjects with the HOTV matching test, this test was introduced at the 4.0 year visit and the 4.25 year visit by experienced site personnel.</description>
          <population>One patient in the intraocular lens group was lost to follow-up.at age 18 months. A second patient in that group had developmental delay and the visual acuity could not be assessed. Therefore, the visual acuity measurements at 4.5 years of age are reported for 55 of the 57 patients randomized to the intraocular lens group.</population>
          <units>logMAR units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.30" upper_limit="1.60"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.40" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity - Subjective Assessment at Age 10 Years.</title>
        <description>Visual acuity assessment using the E-ETDRS protocol will be performed by certified site personnel; patients should be in their best optical correction as determined by the PI either recently or just before the EVA test</description>
        <time_frame>Phase 3 Age 10 Years</time_frame>
        <posting_date>03/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With 1 or More Intraoperative Complications at Cataract Surgery</title>
        <description>Percent of Patients with 1 or More Intraoperative Complications at Cataract Surgery</description>
        <time_frame>Cataract surgery immediately after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aphakic Contact Lens</title>
            <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly.
hyperopic correction of infant surgical aphakia with Contact Lens: optical correction of infant surgical aphakia with Contact lens</description>
          </group>
          <group group_id="O2">
            <title>Aphakic Intraocular Lens</title>
            <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: At the time of surgery to remove the cataractous natural lens, an intraocular lens was implanted to correct the large hyperopic refractive error induced by the cataract surgery.
primary implantation of aphakic intraocular lens: optical correction of surgical aphakia with intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With 1 or More Intraoperative Complications at Cataract Surgery</title>
          <description>Percent of Patients with 1 or More Intraoperative Complications at Cataract Surgery</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="O2" value="28" lower_limit="17" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With 1 or More Adverse Events</title>
        <time_frame>Study enrollment to age 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aphakic Contact Lens</title>
            <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
          </group>
          <group group_id="O2">
            <title>Aphakic Intraocular Lens</title>
            <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With 1 or More Adverse Events</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="42" upper_limit="69"/>
                    <measurement group_id="O2" value="81" lower_limit="68" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parenting Stress</title>
        <description>The PSI is a 120-item validated self-report measure of parenting stress. PSI is a continuous scale measuring stress with a range of 131 (low stress) to 320 (high stress); the average person's stress scores are between 188 and 252.</description>
        <time_frame>Phase 1 - 3 months post surgery</time_frame>
        <population>All those who completed the PSI 3 months after surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Aphakic Contact Lens</title>
            <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
          </group>
          <group group_id="O2">
            <title>Aphakic Intraocular Lens</title>
            <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Parenting Stress</title>
          <description>The PSI is a 120-item validated self-report measure of parenting stress. PSI is a continuous scale measuring stress with a range of 131 (low stress) to 320 (high stress); the average person's stress scores are between 188 and 252.</description>
          <population>All those who completed the PSI 3 months after surgery.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.4" spread="35.7"/>
                    <measurement group_id="O2" value="231.1" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT analyses comparing parents of children randomized to receive an IOL to those left aphakic.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Occlusion Therapy</title>
        <description>Parental report of the number of hours children wore an patch to occlude the fellow eye.</description>
        <time_frame>Phase 1 - 12 months follow-up</time_frame>
        <population>Analysis is limited to those with at least 3 reports of adherence before 12 months of age.</population>
        <group_list>
          <group group_id="O1">
            <title>Aphakic Contact Lens</title>
            <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
          </group>
          <group group_id="O2">
            <title>Aphakic Intraocular Lens</title>
            <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Occlusion Therapy</title>
          <description>Parental report of the number of hours children wore an patch to occlude the fellow eye.</description>
          <population>Analysis is limited to those with at least 3 reports of adherence before 12 months of age.</population>
          <units>Hours patched per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="1.55"/>
                    <measurement group_id="O2" value="3.63" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parenting Stress</title>
        <description>The PSI is a 120-item validated self-report measure of parenting stress. PSI is a continuous scale measuring stress with a range of 131 (low stress) to 320 (high stress); the average person's stress scores are between 188 and 252</description>
        <time_frame>Phase 1 - Age 12 Months</time_frame>
        <population>All those who completed the PSI 3 months after surgery and the PSI at age 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Aphakic Contact Lens</title>
            <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
          </group>
          <group group_id="O2">
            <title>Aphakic Intraocular Lens</title>
            <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
          </group>
        </group_list>
        <measure>
          <title>Parenting Stress</title>
          <description>The PSI is a 120-item validated self-report measure of parenting stress. PSI is a continuous scale measuring stress with a range of 131 (low stress) to 320 (high stress); the average person's stress scores are between 188 and 252</description>
          <population>All those who completed the PSI 3 months after surgery and the PSI at age 12 months</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.6" spread="34.4"/>
                    <measurement group_id="O2" value="208.3" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITT comparison of mean PSI scores</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.295</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Ocular adverse events occurring the day after enrollment until the follow-up visit at 5 years of age are reported.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aphakic Contact Lens</title>
          <description>optical correction of infant aphakia with aphakic Contact lens
INTERVENTION: aphakic contact lens</description>
        </group>
        <group group_id="E2">
          <title>Aphakic Intraocular Lens</title>
          <description>optical correction of infant aphakia with aphakic Intraocular Lens
INTERVENTION: aphakic intraocular lens</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Standard Terminology</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lens reproliferation into visual axis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pupillary membrane</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Corectopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Glaucoma suspect</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Contact lens related adverse event</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Retinal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hyphema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Retained cortex</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Phthisis bulbi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Corneal edema lasting more than 30 days</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Wound leak or dehisence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Intraocular lens capture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott R Lambert, MD, Study Chairman</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-498-4242</phone>
      <email>lambert7@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

